TOKYO and CAMBRIDGE, Mass., Jan 27, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the European Medicines Agency (EMA) has accepted a […]
TOKYO, Jan 19, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that fully-fledged operations and business activities have begun at Eisai Israel Ltd., a pharmaceutical sales […]
TOKYO, Nov 7, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for muscle relaxant Myonal […]
TOKYO, Oct 4, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced that, as part of the strategic investment towards the realization of its medium-term business plan “EWAY […]
TOKYO, Aug 9, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and LIFENET INSURANCE COMPANY announced today that they have entered into a capital and business alliance agreement […]
TOKYO, Jul 26, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co. Ltd announced today that the company will present research from its Alzheimer’s disease (AD) pipeline, including new data […]
TOKYO, Apr 1, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that Eisai has acquired a majority of the shares issued by Arteryex Inc., a company […]
TOKYO, Mar 15, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer’s disease collaboration agreement with Biogen Inc. […]
CAMBRIDGE, Mass., and TOKYO, Mar 15, 2022 – (JCN Newswire via SEAPRWire.com) – Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. announced today that the companies have amended their existing […]
TOKYO, Mar 4, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has initiated a submission to the Pharmaceuticals and Medical Devices […]
TOKYO, Jan 6, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has entered into a License Agreement granting the exclusive rights for global research, […]
TOKYO, Nov 4, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it launches the “Open Network Lab BioHealth Dementia Innovation Challenge (Onlab Bio Dementia)”, a […]
TOKYO, Sep 14, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has joined “RE100”, the global environmental initiative that aims to shift the electricity […]
TOKYO, Aug 31, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and FUJI YAKUHIN CO., LTD. announced today that they have concluded a license agreement concerning dotinurad (generic […]
Tokyo and New York, Jun 18, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the companies have entered into […]
TOKYO, Jun 15, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for the antiepileptic agent […]
TOKYO, May 11, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has pledged to reduce greenhouse gas (GHG) emission which causes global warming, with […]
TOKYO, Mar 31, 2021 – (JCN Newswire via SEAPRWire.com) – KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., and Eisai Co., Ltd. have entered into a license agreement […]
TOKYO, Mar 22, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it was selected as one of winners of the Ministry of Economy, Trade and […]
TOKYO, Nov 18, 2020 – (JCN Newswire) – Gilead Sciences K.K. and Eisai Co., Ltd. today announced that Jyseleca (filgotinib maleate 200 mg and 100 mg tablets), a new once-daily, […]
